Literature DB >> 11486303

Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City.

J P Burke1.   

Abstract

Errors in antimicrobial prophylaxis for surgical patients remain one of the most frequent types of medication errors in hospitals. Failure to administer the first dose of antimicrobial prophylaxis within the 2-h window of time before incision is associated with 2- to 6-fold increases in rates of surgical site infection. Optimal use of antimicrobial prophylaxis includes proper case selection; use of appropriate agents; proper dosing, route of administration, timing, and duration; and intraoperative dosing when appropriate. Effective use of antimicrobial prophylaxis also requires monitoring of and feedback on patterns of use. Programs to improve antimicrobial prophylaxis should be multidisciplinary and should aim to improve use of medications, not simply to change physician practice patterns. The LDS Hospital experience demonstrates the clinical and financial benefits of such a program and also shows the pitfalls of and great difficulties associated with changing systems of care.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486303     DOI: 10.1086/321861

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Total knee replacement surgery and surgical site infection: a prospective audit.

Authors:  Thomas W Austin; Marilyn A Austin; Brenda Coleman; M Jamjoom; A O Al Thaqafi
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

2.  Exploring obstacles to proper timing of prophylactic antibiotics for surgical site infections.

Authors:  J A Tan; V N Naik; L Lingard
Journal:  Qual Saf Health Care       Date:  2006-02

3.  A Study on the Usage Pattern of Antimicrobial Agents for the Prevention of Surgical Site Infections (SSIs) in a Tertiary Care Teaching Hospital.

Authors:  Afzal Khan A K; Mirshad P V; Mohammed Rafiuddin Rashed; Gausia Banu
Journal:  J Clin Diagn Res       Date:  2013-02-27

4.  Application of ATC/DDD methodology to evaluate perioperative antimicrobial prophylaxis.

Authors:  Serife Akalin; Selda Sayin Kutlu; Bayram Cirak; Saadettin Yilmaz Eskiçorapcı; Dilek Bagdatli; Semih Akkaya
Journal:  Int J Clin Pharm       Date:  2011-12-30

5.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

6.  Update on the Epidemiology and Prevention of Surgical Site Infections.

Authors:  Tae Chong; Robert Sawyer
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

7.  Is there an improvement of antibiotic use in China? Evidence from the usage analysis of combination antibiotic therapy for type I incisions in 244 hospitals.

Authors:  Wen-Juan Zhou; Zhen-Ni Luo; Chang-Min Tang; Xiao-Xu Zou; Lu Zhao; Peng-Qian Fang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

8.  Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines.

Authors:  Yan Zhang; Ken Harvey
Journal:  Aust New Zealand Health Policy       Date:  2006-05-30

9.  Timing of surgical antibiotic prophylaxis administration: complexities of analysis.

Authors:  Carrie Cartmill; Lorelei Lingard; Glenn Regehr; Sherry Espin; John Bohnen; Ross Baker; Lorne Rotstein
Journal:  BMC Med Res Methodol       Date:  2009-06-23       Impact factor: 4.615

10.  Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital.

Authors:  Hai-Xia Zhang; Xin Li; Hai-Qin Huo; Pei Liang; Jin-Ping Zhang; Wei-Hong Ge
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.